Capstone Holding Corp. lowers convertible note conversion price to $1.00
Sheena Jonathan, co-founder and director of Natera, Inc. (NASDAQ:NTRA), recently sold a significant amount of the company’s stock, according to a filing with the Securities and Exchange Commission. The transactions, carried out on March 17 and 18, 2025, involved the sale of shares totaling $856,410. The sale comes as Natera’s stock has shown remarkable strength, delivering a 62.4% return over the past year, according to InvestingPro data.
The sales were executed at prices ranging from $145.0942 to $146.8148 per share, with the stock currently trading at $150.87. Jonathan’s sales were conducted through a Rule 10b5-1 trading plan, a pre-arranged trading strategy that allows insiders to sell stocks in a manner that avoids concerns about insider trading. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with 10+ additional exclusive insights available to subscribers.
Following these transactions, Jonathan retains ownership of 258,949 shares directly and a further 84,994 shares indirectly through Caraluna Trusts. The transactions were part of a broader strategy to manage tax obligations related to vesting restricted stock units and were conducted with transparency and adherence to regulatory guidelines. The company maintains a strong financial position with a current ratio of 4.0 and impressive revenue growth of 56.75% in the last twelve months, as reported by InvestingPro.
In other recent news, Natera has reported a robust fourth-quarter 2024 performance, exceeding Wall Street expectations with a revenue of $476 million, a 53% increase year-over-year. The company’s earnings per share were reported at -$0.41, better than the forecasted -$0.49. Natera’s gross margins also improved significantly to 63%, up from 51% the previous year, with a cash flow generation of $46 million during the quarter. Meanwhile, Natera has initiated the HEROES clinical trial in France to explore the de-escalation of therapy in metastatic HER2+ breast cancer patients, using their Signatera test to guide treatment decisions.
In terms of analyst ratings, both TD Cowen and Canaccord Genuity have maintained a Buy rating on Natera, with a price target set at $195. TD Cowen highlighted the company’s 2025 guidance as promising, with sales projections surpassing consensus estimates by about 5%. Canaccord Genuity’s optimism is bolstered by Natera’s fourth-quarter results, which exceeded preliminary estimates, and the company’s expectation of continued strong revenue growth in 2025. The firm’s analysts also noted the potential benefits from improved Medicare Advantage rates and upcoming biomarker legislation.
These developments reflect Natera’s strategic focus on growth and innovation, as well as the positive reception of its financial guidance and clinical advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.